Last updated: 15 June 2019 at 1:26am EST

Susan E. Barrowcliffe Net Worth




The estimated Net Worth of Susan E. Barrowcliffe is at least $1.4 Millón dollars as of 19 November 2018. Susan Barrowcliffe owns over 40,000 units of Aimmune Therapeutics Inc stock worth over $1,402,250 and over the last 9 years Susan sold AIMT stock worth over $0.

Susan Barrowcliffe AIMT stock SEC Form 4 insiders trading

Susan has made over 9 trades of the Aimmune Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Susan exercised 40,000 units of AIMT stock worth $120,800 on 19 November 2018.

The largest trade Susan's ever made was exercising 75,000 units of Aimmune Therapeutics Inc stock on 2 January 2018 worth over $226,500. On average, Susan trades about 16,154 units every 57 days since 2016. As of 19 November 2018 Susan still owns at least 49,375 units of Aimmune Therapeutics Inc stock.

You can see the complete history of Susan Barrowcliffe stock trades at the bottom of the page.



What's Susan Barrowcliffe's mailing address?

Susan's mailing address filed with the SEC is 8000 Marina Blvd #200, Brisbane, CA 94005, USA.

Insiders trading at Aimmune Therapeutics Inc

Over the last 9 years, insiders at Aimmune Therapeutics Inc have traded over $19,285,948 worth of Aimmune Therapeutics Inc stock and bought 61,698,079 units worth $2,225,231,200 . The most active insiders traders include Des Produits Nestle S.A. So..., Patrick G Enright y Des Produits Nestle S.A.Nes.... On average, Aimmune Therapeutics Inc executives and independent directors trade stock every 22 days with the average trade being worth of $21,038,606. The most recent stock trade was executed by Des Produits Nestle S.A. So... on 13 October 2020, trading 54,117,287 units of AIMT stock currently worth $1,867,046,402.



What does Aimmune Therapeutics Inc do?



Complete history of Susan Barrowcliffe stock trades at Aimmune Therapeutics Inc

Persona
Trans.
Transacción
Precio total
Susan E. Barrowcliffe
General Manager y Europe
Uso de opción $120,800
19 Nov 2018
Susan E. Barrowcliffe
General Manager y Europe
Uso de opción $226,500
2 Jan 2018
Susan E. Barrowcliffe
General Manager y Europe
Uso de opción $60,400
25 Sep 2017
Susan E. Barrowcliffe
General Manager y Europe
Uso de opción $55,538
5 Sep 2017
Susan E. Barrowcliffe
General Manager y Europe
Uso de opción $1,510
27 Jul 2017
Susan E. Barrowcliffe
General Manager y Europe
Uso de opción $18,452
21 Jul 2017
Susan E. Barrowcliffe
General Manager y Europe
Uso de opción $45,300
3 Jul 2017
Susan E. Barrowcliffe
General Manager y Europe
Uso de opción $60,400
11 Nov 2016
Susan E. Barrowcliffe
General Manager y Europe
Uso de opción $45,300
8 Nov 2016


Aimmune Therapeutics Inc executives and stock owners

Aimmune Therapeutics Inc executives and other stock owners filed with the SEC include: